Compound library/Primary-source evidence guide

Thymosin Alpha-1

Human immune literature, country-specific approvals, and evidence limits without protocol advice

Thymosin alpha-1, also known as thymalfasin, is an immune-modulating peptide with published clinical literature in selected infectious-disease settings. This Dosi guide separates evidence for specific studied products and populations from broad online claims about immune boosting, longevity, or routine wellness use.

Editorial status

This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: .

It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.

Product and regulatory distinctions

A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.

Thymalfasin products

Regulatory status is country and product specific; this page does not identify a current FDA-approved thymosin alpha-1 drug product in the United States.

Current source

Online peptide products

Products sold for research, wellness, or compounding may not have undergone premarket review for safety, effectiveness, or quality.

Current source

Sport context

Athletes subject to anti-doping rules should verify peptide status with the current WADA list and sport authority.

Current source

Claim-by-claim evidence map

Each finding is tied to the population and product actually studied. Trial results are not personal predictions.

Randomized human trial

A large phase 3 trial did not show a mortality benefit from thymosin alpha-1 in adults with sepsis.

Population
1,089 adults with Sepsis-3 sepsis in the modified intention-to-treat analysis of a multicenter, double-blind trial.
Finding
Twenty-eight-day all-cause mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo (hazard ratio 0.97, 95% CI 0.76 to 1.24; P=0.82).
Limits
This disease-specific adjunctive trial does not test immune boosting, prevention, longevity, wellness use, or gray-market products in healthy adults.
Thymosin alpha 1 for the treatment of sepsis (TESTS): a multicentre, double blinded, randomised, placebo controlled, phase 3 trial
Randomized human trial

A smaller phase III chronic-hepatitis-B trial did not confirm a statistically conclusive complete-response advantage over placebo.

Population
97 adults with HBV-DNA-positive and HBeAg-positive chronic hepatitis B.
Finding
The prespecified complete response occurred in 14% of the thymosin alpha-1 group and 4% of the placebo group (P=0.084).
Limits
The study was small, indication-specific, and does not support general immune or wellness claims.
Thymosin treatment of chronic hepatitis B: a placebo-controlled multicentre study
Unsupported or anecdotal

FDA has identified unresolved characterization, impurity, and immunogenicity concerns for compounded thymosin alpha-1.

Population
U.S. compounding-policy review, not a clinical outcome population.
Finding
FDA's 2024 review described peptide-related impurities and inadequate information to determine the extent of potential immunogenicity and safety risks.
Limits
This is a U.S. regulatory assessment; it does not determine another country's authorization or prove that every individual product is defective.
Thymosin Alpha-1: Pharmacy Compounding Advisory Committee briefing document

What this evidence does not answer

  • No broad evidence base establishes thymosin alpha-1 as a general immune, anti-aging, or wellness intervention for healthy adults.
  • Long-term safety for repeated off-label or gray-market use is not established by product marketing.
  • Evidence from a named product or country cannot verify identity, sterility, or strength of an online vial.

Useful information to organize between visits

  • Exact product name and source
  • Reason for use and concurrent medicines or immune conditions
  • Dates of exposure and symptoms
  • Any lab or clinical follow-up ordered by a clinician

Questions to bring to a clinician or pharmacist

  1. 1.Is there a licensed product and indication relevant to my country?
  2. 2.Could immune modulation be risky with my condition or medicines?
  3. 3.What established alternatives fit the reason I am considering this?

Primary sources

  1. Thymosin alpha 1 for the treatment of sepsis (TESTS): a multicentre, double blinded, randomised, placebo controlled, phase 3 trialBMJ · Published January 22, 2025 · Accessed July 12, 2026
  2. Thymosin treatment of chronic hepatitis B: a placebo-controlled multicentre studyJournal of Viral Hepatitis · Published 1999-09 · Accessed July 12, 2026
  3. Thymosin Alpha-1: Pharmacy Compounding Advisory Committee briefing documentU.S. Food and Drug Administration · Published 2024 · Accessed July 12, 2026
  4. Drugs@FDA: FDA-Approved DrugsU.S. Food and Drug Administration · Published Current database · Accessed July 12, 2026
  5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration · Published Updated 2026 · Accessed July 12, 2026
  6. 2026 Prohibited ListWorld Anti-Doping Agency · Published 2026 · Accessed July 12, 2026

Turn scattered notes into a useful treatment history

Dosi organizes timing, locations, symptoms, reminders, and questions for your next appointment. It does not prescribe or replace your care team.

Start tracking free